Robust guidelines for full body treatment
Sinclair experts have collaborated to create a comprehensive reconstitution and dilution chart, ensuring easy and consistent preparation for each area. The PLLA in-person training consists of two levels; foundation and advanced. These charts are made available on level completion.
The Expert Guide * for PLLA collagen stimulator for face and body Foundation Level Injectors Global Experts have collaborated to create a comprehensive reconstitution and dilution chart, ensuring easy and consistent preparation in each area. This chart is only intended for foundation level injectors who have completed the Entry-Level PLLA In-Person Training and should be used for injecting in these specified areas. To minimise adverse events, use less product, in lower concentrations, with higher dilutions.
PLLA protocols
One-page protocols
Video protocols
PLLA Foundation Level Areas
Face
Buttocks
Abdomen
Thigh and upper knees
Cellulite
Indications
Type of product
PLLA V
PLLA X
PLLA V
PLLA V
PLLA V
Reconstitution in vial Add sterile water to PLLA vial to get PLLA 14 mg/dl
15 mL sterile water + 1 vial (210 mg)
40 mL of sterile water + 1 vial (630 mg)
15 mL sterile water + 1 vial (210 mg)
15 mL sterile water + 1 vial (210 mg)
15 mL sterile water + 1 vial (210 mg)
Time from reconstitution †
5 mins
10 mins
5 mins
5 mins
5 mins
+ 2 mL lidocaine Before treatment, add 5 mL sterile water
2% lidocaine This is recommended but not compulsory ‡
+ 1 mL lidocaine
+ 5 mL lidocaine
+ 2 mL lidocaine
+ 2 mL lidocaine
Dilution in syringe Double dilution = PLLA 7 mg/dl Triple dilution = PLLA 4.7 mg/dl
Double dilution: In 1 x 3 mL Luer lock syringe: 1.5 mL of reconstituted solution + 1.5 mL of sterile water
Double dilution: In 10 ml syringe: 5 mL of resconstituted solution + 5 mL of sterile water per syringe (volume 1:1) Or triple dilution: In 10ml syringes: 2.5 mL of reconstituted solution +5 mL of sterile water per syringe (volume 1:2)
First session: 45–90 mL (630 mg) per 10 x 10 cm (100 cm 2 ) area Second session: 45–90 mL (630 mg) per 10 x 10 cm (100 cm 2 ) area
15–30 mL (up to 2 vials) or 5 mL per 10 x 10 cm (100 cm 2 ) area Refer to page 2, ‘Performing undermining in the abdominal area’
5–10 mL per knee 555 Rule: 5 mL undermining + 5 mL double diluted solution per 5 x 5 cm (25 cm 2 ) area
Max. amount of product per side
7.5 mL (105 mg)
7.5 mL (105 mg)
Undermining § (4:1) (Saline:2% Lidocaine)
10 mL of solution per 10 x 10 cm (100 cm 2 ) area
5 mL of solution per 10 x 10 cm (100 cm 2 ) area
N/A
5 mL of solution
N/A
Anatomical depth of injection
Subcutaneous
Device (cannula gauge) ¶
21–22G cannula
18G cannula
18–23G cannula
21–22G cannula
21–22G cannula
*The content of this document has been prepared by our panel of experts. Any opinions, views, advice provided are those of healthcare practitioners. Sinclair does not provide any warranty and does not accept any liability for the opinions, views or advice expressed. † Internal Data on file for Time to Reconstitution. To reduce the risk of nodule formation, ensure sufficient hydration. ‡ Please consider the cumulative dose of lidocaine by taking into account the volumes added to both the undermining solution and the PLLA vial to avoid lidocaine toxicity. Using 1% or 2% lidocaine with epinephrine may help reduce toxicity and minimise bruising. § Undermining (hydrodissection) is the technique of bluntly dissecting the dermal layer away from the underlying connective tissue, to allow more homogenous spread of the product. In some areas, it is mandatory to undermine. Please refer to the video on page 2 on how to undermine on the abdominal area. ¶ To reduce the risk of clogging or obstruction of the cannula, use cannulas between 18G and 23G.
Prepared in cooperation with Sinclair Medical Affairs and Sinclair College BR00849351-001-000 | October 2024
PLLA is intended to be administrated via injection by a trained and authorised health professional. Opinions and methods presented here reflect the physician experience. Refer to instructions for details of specific indications. CE 1023: PLLA devices are intended for increasing the volume of depressed skin areas, particularly to correct skin depressions
The content of this document has been prepared by our panel of experts. Any opinions, views, advice provided are those of healthcare practitioners. Sinclair does not provide any warranty and does not accept any liability for the opinions, views or advice expressed. BR00849351-001-000 | October 2024
Features Before & After Results 1 2 3 Why Lanluma
Product Summary
Training Resources
Mode of Action
Clinical Data
Safety
MaiLi
Lanluma Ellansé Lanluma
PRODUCT COMPARISON
13
Made with FlippingBook Digital Publishing Software